Antineutrophil cytoplasmic antibody-associated vasculitis : insights into relapse risk and future management directions
(2025) In Frontiers in Immunology 16.- Abstract
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has a relapsing-remitting course and, even with the availability of effective maintenance therapies such as rituximab, relapse rates remain high. Relapse is associated with the accrual of organ damage stemming from both the underlying disease and from the effects of AAV treatments; thus, early detection and proactive prevention are crucial. AAV study populations typically include mixed cohorts of patients with new-onset and relapsing disease. Although data specifically addressing re-induction of remission after relapse are limited, available evidence suggests high remission rates when rituximab is combined with glucocorticoids. However, the balance between effective... (More)
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has a relapsing-remitting course and, even with the availability of effective maintenance therapies such as rituximab, relapse rates remain high. Relapse is associated with the accrual of organ damage stemming from both the underlying disease and from the effects of AAV treatments; thus, early detection and proactive prevention are crucial. AAV study populations typically include mixed cohorts of patients with new-onset and relapsing disease. Although data specifically addressing re-induction of remission after relapse are limited, available evidence suggests high remission rates when rituximab is combined with glucocorticoids. However, the balance between effective disease control and the potential treatment-related side effects must be carefully considered, and new therapeutic options may help improve this tradeoff. The aim of this review is to explore what is known about relapse risk and relapse management while considering emerging pathogenic and therapeutic paradigms.
(Less)
- author
- Alberici, Federico ; Flossmann, Oliver ; Lamprecht, Peter ; Loudon, Kevin W. ; Padoan, Roberto ; Popov, Tamara ; Salvarani, Carlo and Mohammad, Aladdin J. LU
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- AAV relapse, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), remission re-induction
- in
- Frontiers in Immunology
- volume
- 16
- article number
- 1655326
- publisher
- Frontiers Media S. A.
- external identifiers
-
- scopus:105017832882
- pmid:41050707
- ISSN
- 1664-3224
- DOI
- 10.3389/fimmu.2025.1655326
- language
- English
- LU publication?
- yes
- id
- 41d9175d-2e73-4b4c-9f1b-7d959451ce4c
- date added to LUP
- 2025-12-05 14:35:42
- date last changed
- 2025-12-06 03:00:08
@article{41d9175d-2e73-4b4c-9f1b-7d959451ce4c,
abstract = {{<p>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has a relapsing-remitting course and, even with the availability of effective maintenance therapies such as rituximab, relapse rates remain high. Relapse is associated with the accrual of organ damage stemming from both the underlying disease and from the effects of AAV treatments; thus, early detection and proactive prevention are crucial. AAV study populations typically include mixed cohorts of patients with new-onset and relapsing disease. Although data specifically addressing re-induction of remission after relapse are limited, available evidence suggests high remission rates when rituximab is combined with glucocorticoids. However, the balance between effective disease control and the potential treatment-related side effects must be carefully considered, and new therapeutic options may help improve this tradeoff. The aim of this review is to explore what is known about relapse risk and relapse management while considering emerging pathogenic and therapeutic paradigms.</p>}},
author = {{Alberici, Federico and Flossmann, Oliver and Lamprecht, Peter and Loudon, Kevin W. and Padoan, Roberto and Popov, Tamara and Salvarani, Carlo and Mohammad, Aladdin J.}},
issn = {{1664-3224}},
keywords = {{AAV relapse; antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; granulomatosis with polyangiitis (GPA); microscopic polyangiitis (MPA); remission re-induction}},
language = {{eng}},
publisher = {{Frontiers Media S. A.}},
series = {{Frontiers in Immunology}},
title = {{Antineutrophil cytoplasmic antibody-associated vasculitis : insights into relapse risk and future management directions}},
url = {{http://dx.doi.org/10.3389/fimmu.2025.1655326}},
doi = {{10.3389/fimmu.2025.1655326}},
volume = {{16}},
year = {{2025}},
}